SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

4D Molecular Therapeutics Q3 net loss widens on higher costs

4D Molecular Therapeutics Q3 net loss widens on higher costs Overview US gene therapy developer's Q3

FDMT

Related stories